Cas9 (CMV, no selection) Integrase-Deficient Lentivirus
544.75 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 500 - IDLV023
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 1x10^7 IFU/ml x 200ul
Parameters
| Storage and shipping | (-80oC) |
|---|---|
| Storage and shipping | With |
IDLV023
Cas9 (CMV, no selection) Integrase-Deficient Lentivirus
Integrase-Deficient Lentivirus expressing human codon CAS9 endonuclease under CMV promoter. Do not contain any selection marker.
544.75 €
IDLV024
Cas9 (EF1a, no selection) Integrase-Deficient Lentivirus
Integrase-Deficient Lentivirus expressing human codon CAS9 endonuclease under EF1a promoter. Do not contain any selection marker.
544.75 €
IDLV009
Cas9 (CMV, Bsd) Integrase-Deficient Lentivirus
Integrase-Deficient Lentivirus expressing human codon CAS9 endonuclease under CMV promoter, containing Blasticidin antibiotic marker, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.
544.75 €
78055
TCR CRISPR/Cas9 Lentivirus (Integrating)
The T-Cell Receptor (TCR) is found on the surface of T-cells and is responsible for recognizing antigens bound to MHC (Major Histocompatibility Complex) molecules. Activation of the TCR results in activation of downstream NFAT signaling. The TCR consists of a heterodimer of two different protein chains, of which the alpha (α) and beta (β) chains are the predominant chains._x000D_<br />The TCR CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TRAC (T-Cell Receptor Alpha Constant) and human TRBC1 (T-Cell Receptor Beta Constant 1) regions of the α and β chains._x000D_<br />The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_
1342.5 €
78053
LAG3 CRISPR/Cas9 Lentivirus (Integrating)
Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T-cells, Natural Killer cells, B-cells, and plasmacytoid dendritic cells. Its main ligand is the MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T-cells in a similar fashion as CTLA-4 and PD-1, and has been reported to play a role in T-reg suppressive function. A number of LAG3 antibodies are in preclinical development for the treatment of cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1, because antibodies targeting CTLA-4 or PD-1 only activate effector T-cells while failing to inhibit T-reg activity, whereas an antagonist LAG3 antibody can both activate effector T-cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) T-reg suppressive activity.<br /><br />The LAG3 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human LAG3 (GenBank Accession #NM_002286) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ _x000D_
1342.5 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Pneumokocker – vad är det som angriper våra barn?
30 August 2025
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Stroke – viktig information
8 August 2025